Literature DB >> 30041538

Reduced Lexical Access to Verbs in Individuals With Subjective Cognitive Decline.

Joël Macoir1,2, Anne Lafay1,2, Carol Hudon1,3.   

Abstract

The detection of cognitive impairment in individuals with subjective cognitive decline (SCD) may improve detection of the emergence of Alzheimer's disease (AD) pathology. This detection is challenging, however, given the lack of sensitive assessment tools. The main objective of this study was to determine the potential contribution of word production tasks to the detection of cognitive impairment in SCD. The performances of 20 individuals with SCD, healthy controls (HCs), and individuals with mild cognitive impairment (MCI) were compared on object and action naming and free fluency tasks. Participants with SCD performed similarly to HCs, while both groups differed significantly from participants with MCI in object naming and object fluency. Results showed that participants with SCD were at the midpoint between HCs and participants with MCI in action naming. They also revealed a HCs > SCD = MCI pattern in action fluency. This study provides evidence that verb production is impaired in SCD and that SCD is a pre-MCI condition.

Entities:  

Keywords:  Alzheimer’s disease; action fluency; action naming; early detection; language; subjective cognitive decline

Mesh:

Year:  2018        PMID: 30041538     DOI: 10.1177/1533317518790541

Source DB:  PubMed          Journal:  Am J Alzheimers Dis Other Demen        ISSN: 1533-3175            Impact factor:   2.035


  2 in total

1.  The Joint Effects of Acoustic and Linguistic Markers for Early Identification of Mild Cognitive Impairment.

Authors:  Fengyi Tang; Jun Chen; Hiroko H Dodge; Jiayu Zhou
Journal:  Front Digit Health       Date:  2022-02-11

2.  Neural Correlates of Verb Fluency Performance in Cognitively Healthy Older Adults and Individuals With Dementia: A Pilot fMRI Study.

Authors:  Eun Jin Paek; Laura L Murray; Sharlene D Newman
Journal:  Front Aging Neurosci       Date:  2020-03-20       Impact factor: 5.750

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.